
Opinion|Videos|February 3, 2025
COMFORT Studies in Context: Understanding Response Parameters and Long-Term Outcomes
Author(s)Aaron T. Gerds, MD, MS, Jeanne Palmer, MD
Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with myelofibrosis, providing crucial data to inform current treatment approaches.
Advertisement
Episodes in this series

Advertisement
Related to this article

During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.

Ongoing phase 3 research will help clarify the long-term benefit of amivantamab in head and neck squamous cell carcinoma.

iSCIB1+ advances toward a global phase 3 trial in advanced melanoma, with closer guidance from the FDA.

The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.

FDA approval of pimicotinib adds another CSF1R inhibitor for tenosynovial giant cell tumor, says Andrew J. Wagner, MD, PhD, of Dana-Farber Cancer Institute.

The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.

During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
2
FDA Removes PCNSL Limitation From Liso-Cel Label
3
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastric Cancer
4
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
5

